FDA Approves Emflaza for Duchenne Muscular Dystrophy

Share this content:
FDA Approves Emflaza for Duchenne Muscular Dystrophy
FDA Approves Emflaza for Duchenne Muscular Dystrophy

FRIDAY, Feb. 10, 2017 (HealthDay News) -- Emflaza (deflazacort) has been approved by the U.S. Food and Drug Administration to treat Duchenne muscular dystrophy (DMD) in patients 5 years and older, the agency said Thursday in a news release.

The corticosteroid is designed to reduce inflammation and suppress the immune system in patients with DMD, the most common type of muscular dystrophy. The FDA said it's the first corticosteroid approved to treat DMD.

Emflaza was evaluated in a clinical study of 196 males aged 5 to 15, all with documented mutation of the dystrophin gene and onset of DMD symptoms before age 5. After 12 weeks, patients taking the drug showed muscle strength improvement, compared with those who took a placebo.

Side effects, similar to those caused by other corticosteroid medications, included facial puffiness, weight gain, increased appetite, upper respiratory tract infection, cough, and increased need to urinate, the FDA said.

Emflaza is marketed by Marathon Pharmaceuticals, based in Northbrook, Ill.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Influenza Vaccine 48 Percent Effective Overall

CDC: Influenza Vaccine 48 Percent Effective Overall

More severe H3N2 strain a factor in reduced coverage

D.C. Zika Tests Were Flawed

D.C. Zika Tests Were Flawed

One of the issues with tests was a mathematical error

Experts Warn of Health Threats From Climate Change

Experts Warn of Health Threats From Climate Change

Additional 250,000 deaths/year projected from heat stress, malnutrition, infectious diseases

is free, fast, and customized just for you!

Already a member?

Sign In Now »